NCT02768961View on ClinicalTrials.gov

Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

May 10, 2017

Study Completion Date

May 10, 2017

Conditions
Hepatitis C
Interventions
DRUG

sofosbuvir

"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"

DRUG

ledipasvir

"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"

Trial Locations (1)

39740

"Penitentiary El Dueso. Cantabria. Spain", Santoña

All Listed Sponsors
lead

Instituto de Investigación Marqués de Valdecilla

OTHER

NCT02768961 - Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) | Biotech Hunter | Biotech Hunter